Opus Genetics (IRD) EBIT Margin (2010 - 2026)

Opus Genetics (IRD) has 8 years of EBIT Margin data on file, last reported at 665.92% in Q1 2026.

• On a quarterly basis, EBIT Margin fell 43872.0% year-over-year to 665.92% in Q1 2026; TTM through Mar 2026 was 359.13%, a 11187.0% increase from a year earlier, with the FY2025 full-year figure at 271.9%, up 29282.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 665.92%, down from 296.33% in the prior quarter.
• Over the last five years, EBIT Margin for IRD reached as high as 85.85% in Q4 2022 and fell as low as 883.98% in Q4 2024.
• Historically, EBIT Margin has averaged 338.42% across 5 years, with a median of 302.67% in 2025.
• Across the five-year window, EBIT Margin plunged 60224 bps in 2024 and jumped 58766 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 85.85% in 2022, then slumped by 474 bps to 321.05% in 2023, then plunged by 175 bps to 883.98% in 2024, then soared by 66 bps to 296.33% in 2025, then plunged by 125 bps to 665.92% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 665.92% in Q1 2026, 296.33% in Q4 2025, and 269.93% in Q3 2025.